Association of maternal levothyroxine use during pregnancy with offspring birth and neurodevelopmental outcomes: a population-based cohort study

Table 2 Comparison of children born from gestational L-T4 users with reference to children of euthyroid control mothers

Gestational L-T4 users (N = 2125) vs euthyroid control (N = 398,909)
Outcomes	N of cases in exposed (%)	N of cases in unexposed (%)	Crude		PS-weighted ^a
			OR (95% CI)	P-value	OR (95% CI)	P-value
Preterm birth	256 (12.05)	33,462 (8.39)	1.50 (1.32, 1.71)	<0.0001	1.22 (1.07, 1.39)	0.0032
SGA	41 (1.93)	6787 (1.70)	1.14 (0.83, 1.55)	0.42	1.08 (0.79, 1.48)	0.64
			HR (95% CI)	P-value	HR (95% CI)	P-value
ADHD	85 (4.00)	15,152 (3.80)	1.10 (0.89, 1.36)	0.37	1.10 (0.88, 1.37)	0.41
ASD	65 (3.06)	10,827 (2.71)	1.15 (0.90, 1.47)	0.26	1.00 (0.78, 1.29)	1.00

OR odds ratio, HR hazard ratio, PS propensity score, vs versus, ADHD attention-deficit/hyperactivity disorder, ASD autism spectrum disorder, SGA small for gestational age
^aPS-weighted model adjusted for maternal age at delivery, birth year, birth hospital, parity, maternal underlying illness before delivery including pre-existing diabetes, gestational diabetes, epilepsy, hypertension, and psychiatric conditions

ISSN: 1741-7015